With growing optimism about the market, multinational medical enterprises like Roche have invested over 4 billion yuan in China

Recently, executives from multinational medical enterprises like Danaher and AstraZeneca intensively visited China or revealed their plans to visit China. It is becoming a common question for most multinational medical businesses to explore how to support China's high-level opening up and help China's medical industry improve its quality and efficiency.

Roche has invested a total of 4 billion yuan in China

As China has become its second largest market, Roche has continued to refine the industrial chain, including direct investment, strategic cooperation and industrial empowerment, to promote local innovative collaboration. 

Roche’s Asia-Pacific manufacturing bases and R&D centers in China have been expanded for higher production capacity with continued and increased investments of 4 billion yuan.

Guoliang Yao, General Manager of Roche Diagnostics China, said that multinational pharmaceutical businesses expect to further integrate into China's new development pattern and share the opportunities of China's high-level opening up and innovation-driven development, and is willing to support the high-quality development of China's healthcare industry and local biopharmaceutical industry with its own development.

The president of Danaher plans to visit China in March

According to China Daily, Rainer Blair, CEO of Danaher, plans to visit China in mid-March.

Rainer Blair said, "For Danaher, China is a fast-growing strategic market, and we are committed to long-term growth in China. We will significantly increase our production capacity in China to better help our customers achieve the endless possibilities in their lives."

Cytiva, Danaher's biotechnology subsidiary, is reportedly expanding its biotechnology development training center Fast Trak in Shanghai with an investment of approximately 8 million US dollars. 

Pall Corp, Danaher's microelectronics subsidiary, has also accelerated its localization in China.

AstraZeneca is confident in the Chinese market

Wang Lei, AstraZeneca's global executive vice president and president of international business and China, said in an interview with International Financial News, "I believe China has become one of the largest and best healthcare markets in the world. The potential of the Chinese market is huge and will not change just because of the pandemic, and the resilience of the Chinese economy remains strong. China has a population of 1.4 billion while their living standards are gradually improving, life expectancy is rising and treatment for all kinds of diseases is improving. The Chinese market remains the most attractive market in the world."